Flagship Pioneering, LLC
Flagship Pioneering, LLC reported 5 US-listed holdings worth $1.54 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Generate Biomedicines Inc. (68.7%), Moderna, Inc. (21.1%) and Sana Biotechnology Inc. (5.7%). Against the quarter before, it opened 0 positions, added to 0, trimmed 0 and sold out of 0.
Filed before as Flagship Pioneering Inc..
Reported holdings$1.54B+32.6% on Q1 2026
Positions5as many as Q1 2026
The largest ten100.0%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Held
The 5 largest of its 5 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Generate Biomedicines Inc. GENB | 62,673,117 | $1.06 billion | 68.66% | no change |
| Moderna, Inc. MRNA | 4,632,149 | $324.4 million | 21.07% | no change |
| Sana Biotechnology Inc. SANA | 25,001,856 | $87.3 million | 5.67% | no change |
| Foghorn Therapeutics Inc. FHTX | 12,674,120 | $61.8 million | 4.02% | no change |
| Seres Therapeutics Inc - US MCRB | 1,155,850 | $9.1 million | 0.59% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.